The Early Detection Research Network: Biomarker Developmental Laboratories

The summary for the The Early Detection Research Network: Biomarker Developmental Laboratories grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

The Early Detection Research Network: Biomarker Developmental Laboratories: The Division of Cancer Prevention (DCP), National Cancer Institute (NCI), invites new and competing renewal cooperative agreement and NIH intramural applications to continue the national Network that has the responsibility for the development, evaluation, and validation of biomarkers for earlier cancer detection and risk assessment. Biomarkers are defined as cellular, biochemical, and molecular (including genetic and epigenetic) alterations by which a normal, abnormal, or simply biologic process can be recognized or monitored. Biomarkers are measurable in biological media, such as in tissues, cells, or fluids. The Network has four main components Biomarker Developmental Laboratories (BDL), Biomarker Reference Laboratories (formerly known as Biomarker Validation Laboratories), Clinical Epidemiology and Validation Centers (formerly known as Clinical and Epidemiologic Centers), and a Data Management and Coordinating Center (DMCC). The Biomarker Developmental Laboratories have responsibility for the development and characterization of new, or the refinement of existing, biomarkers and assays. The Biomarker Reference Laboratories serve as a Network resource for clinical and laboratory validation of biomarkers, including technological development and refinement. The Clinical Epidemiology and Validation Centers collaboratively conduct clinical and epidemiological research on the Network-wide clinical validation of biomarkers. The Data Management and Coordinating Center supports statistical and computational analysis, informatics infrastructure, and coordinates network-wide meetings and conferences. For further details, see http://www.cancer.gov/edrn. The EDRN Steering Committee (SC) is composed of the Principal Investigators (PIs) in the Network and appropriate NCI staff to coordinate the work of the Network. The purpose of this reissuance is to invite new and competing renewal applications to add additional Biomarker Development Laboratories and to ensure biomarker studies on all cancers of common occurrence are supported. Special emphasis should be placed on cancers of common occurrence, with high priority given to studies of breast, lung, ovarian, colon, pancreatic, and prostate and other less prevalent epithelial cancers, which are the major causes of cancer- related mortality and have yet to be controlled with screening and prevention. Separate RFAs had already been issued to establish the Biomarker Reference Laboratories, Clinical Epidemiology and Validation Centers, and the Data Management and Coordinating Center. Applicants are encouraged to participate in more than one component, because it is recognized that collaboration already exists in individual institutions for clinical testing and validation of biomarkers/reagents.